DOPADecarboxylase抗体;DOPADecarboxylase Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of DOPA Decarboxylase expression in (1) 293T cell lysate; (2) RAW 264 .7 cell lysate.    

  
  

DOPA decarboxylase (DDC), also known as aromatic L-amino acid decarboxylase (AADC), is a pyridoxal phosphate-dependent enzyme that catalyzes the conversion of L-DOPA to dopamine and 5-hydroxytryptophan (5-HTP) to serotonin, critical neurotransmitters and hormones. It plays a vital role in the biosynthesis of monoamines, linking amino acid metabolism to neuroendocrine signaling. Dysregulation of DDC expression or activity is implicated in neurological disorders (e.g., Parkinson’s disease), neuroendocrine tumors, and metabolic conditions, making it a target for research and diagnostics.

DDC antibodies are essential tools for detecting and quantifying this enzyme in biological samples. They are widely used in techniques like Western blotting, immunohistochemistry, and ELISA to study DDC’s tissue distribution, cellular localization, and expression levels in both normal physiology and disease states. Commercially available antibodies are typically raised against specific epitopes of human DDC, with cross-reactivity tested in common model organisms. Validation often includes knockout controls to confirm specificity.

Research applications focus on understanding DDC’s role in neurotransmitter synthesis, tumor biomarker discovery (e.g., in neuroblastoma or small cell lung cancer), and evaluating therapeutic interventions targeting monoamine pathways. These antibodies also aid in diagnosing congenital AADC deficiency, a rare genetic disorder affecting neurotransmitter production.